🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: RSV vaccine formulation 2 dose

Found 30 matching trials

A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Females From 9 to 49 Years of Age

PHASE3

The purpose of this study was to evaluate the reactogenicity, safety and im...

Status

Completed

Location

GSK Investigational Site

Start Date

2022-02-02

Trial ID

NCT05169905

Treatments Being Tested

RSV MAT vaccine dTpa vaccine

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoSmithKline (GSK) Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Pregnant Women and Infants Born to Vaccinated Mothers

PHASE2

The purpose of this study is to assess the safety, reactogenicity and immun...

Status

Withdrawn

Location

GSK Investigational Site

Start Date

2017-07-11

Trial ID

NCT03191383

Treatments Being Tested

RSV vaccine (GSK3003891A) formulation 1 RSV vaccine (GSK3003891A) formulation 2 RSV vaccine (GSK3003891A) formulation 3 Placebo (Formulation buffer S9b)

A Study to Examine Respiratory Combination Vaccines Against Respiratory Syncytial Virus (RSV) and Flu in Older Adults

PHASE1

Substudy A: The study aims to learn about the safety and effects of two new...

Status

Completed

Location

Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich

Start Date

2023-03-09

Trial ID

NCT05788237

Treatments Being Tested

RSVpreF+qIRV qIRV RSVpreF Placebo RSVpreF + qIRV 1.0 mL formulation RSVpreF + qIRV 0.5 mL formulation

Phase II Clinical Trial of Lyophilized Respiratory Syncytial Virus mRNA Vaccine in Adults Aged 50 Years or Above

PHASE2

The primary objective of this study is to evaluate the immunogenicity and s...

Status

Active Not Recruiting

Location

Baise Center For Disease Control & Prevention

Start Date

2025-09-15

Trial ID

NCT07289542

Treatments Being Tested

ABO1105 Placebo

A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old

PHASE1

The primary goal of this study is to evaluate the safety and reactogenicity...

Status

Completed

Location

Accel Research Sites

Start Date

2022-10-14

Trial ID

NCT05585632

Treatments Being Tested

mRNA-1010 mRNA-1345 mRNA-1273.214 mRNA-1045 mRNA-1230

Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV

PHASE1

The purpose of this study is to provide critical information on the safety,...

Status

Completed

Location

GSK Investigational Site

Start Date

2019-04-08

Trial ID

NCT03636906

Treatments Being Tested

RSV (GSK3389245A) lower dose formulation vaccine RSV (GSK3389245A) higher dose formulation vaccine GSK's multicomponent meningococcal B vaccine Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine GSK's pneumococcal polysaccharide conjugate vaccine GSK's meningococcal group A, C, W-135 and Y conjugate vaccine Placebo

Study of an Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers

PHASE1

The primary objectives of the study were: * To assess the safety profile o...

Status

Completed

Location

Matrix Clinical Research-Site Number:8400012

Start Date

2020-09-17

Trial ID

NCT04491877

Treatments Being Tested

RSV vaccine formulation 1 RSV vaccine formulation 2 Placebo

Study to Evaluate the Safety and Immunogenicity of Investigational Vaccines Using the RSV (Respiratory Syncytial Virus) Monovalent Antigen in Healthy Participants 18 to 49 Years of Age

PHASE1

The purpose of this study is to evaluate the safety and immunogenicity of d...

Status

Completed

Location

Site # 0361003

Start Date

2025-07-14

Trial ID

NCT07071558

Treatments Being Tested

RSV vaccine formulation 1 dose RSV vaccine formulation 2 dose RSV vaccine formulation 3 dose RSV vaccine formulation 4 dose RSV vaccine formulation 5 dose RSV vaccine formulation 6 dose RSV vaccine formulation 7 dose RSV vaccine formulation 8 dose

A Phase 2 Study to Describe the Safety and Immunogenicity of Respiratory Syncytial Virus Vaccine IN006 in Healthy Participants Aged 60 Years and Older

PHASE2

The study will evaluate the safety, tolerability, and immunogenicity of 2 d...

Status

Active Not Recruiting

Location

Hunan Provincial Center for Disease Control and Prevention

Start Date

2025-08-13

Trial ID

NCT07128121

Treatments Being Tested

Respiratory Syncytial Virus IN006 Bivalent mRNA Vaccine (IN006)Placebo

A Study of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Diphtheria, Pertussis and Tetanus (Tdap) Viruses Followed by a 2nd Dose of the RSV Vaccine to Healthy Non-Pregnant Women

PHASE2

The purpose of this study is to evaluate the safety, ability of GSK Biologi...

Status

Completed

Location

GSK Investigational Site

Start Date

2019-11-05

Trial ID

NCT04138056

Treatments Being Tested

RSVPreF3 formulation 3 RSVPreF3 formulation 2 Boostrix-ex-US Boostrix-US Placebo

Previous Next